DNA and RNA-based next-generation sequencing for companion diagnostic rearrangement detection in solid tumors
The Oncologist · 05.02.2026 · 31 (3)
DOI: 10.1093/oncolo/oyag001 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 09.01.2026. Verfasst von Rachel B Keller-Evans und 7 weiteren Autor:innen. Beteiligte Einrichtung: Foundation Medicine, Inc., Boston, MA 02210, United States. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Neoplasms, Gene Rearrangement. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
While a well-designed next-generation sequencing-based DNA (DNA-NGS) comprehensive genomic profiling assay can be robust for detecting genomic rearrangements (RE), concurrent RNA-based NGS (RNA-NGS) may improve overall sensitivity. Patients & Methods We examined detection rates of tissue sequencing-based companion diagnostic (CDx) RE (ALK, BRAF, FGFR2/3, METEx14, NTRK1/2/3, NRG1, RET, and ROS1) in a retrospective cohort of 5129 patients who received DNA- and RNA-NGS in parallel in order to quantify the added value of concurrent DNA- and RNA-NGS over DNA-NGS alone.
Results
The prevalence of CDx gene RE was 3.3% (N = 171) across solid tumors and 2.0% (N = 101) within approved tumor types (ITT) across both DNA and RNA. 20% of CDx RE ITT and 26% of CDx gene RE across solid tumors were detected with RNA-NGS only. Detection of NRG1 and NTRK fusions was most improved due to the challenges of baiting these genes on DNA-NGS with 67% of NRG1 RE+ non-small cell lung cancer (NSCLC) and 67% of NTRK RE+ solid tumors identified on RNA alone. A small proportion (4% ITT and 5% across all solid tumors) of CDx gene RE were detected in DNA alone in samples in which RNA could not be sequenced.
Conclusion
A higher rate of CDx RE detection—most significantly for NRG1 and NTRK fusions—was observed using concurrent DNA-NGS and RNA-NGS compared to DNA-NGS alone. Our results highlight the complementary nature of these methods. Given the substantial clinical benefit of RE-targeted therapies, an integrated DNA/RNA profiling strategy should be part of routine clinical care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Foundation Medicine, Inc., Boston, MA 02210, United States.
- Pathology, Upstate Medical University, Syracuse, NY 13210, United States.
ORCID-Profile: Rachel B Keller-Evans, Ole Gjoerup, Richard S P Huang
Zitieren
APA
Keller-Evans, R. B., Lee, J. K., Allen, J. M., Zhong, L., Gjoerup, O., Ross, J. S., Gascó, A., & Huang, R. S. P. (2026). DNA and RNA-based next-generation sequencing for companion diagnostic rearrangement detection in solid tumors. The Oncologist, 31(3). https://doi.org/10.1093/oncolo/oyag001
Vancouver
Keller-Evans RB, Lee JK, Allen JM, Zhong L, Gjoerup O, Ross JS, et al. DNA and RNA-based next-generation sequencing for companion diagnostic rearrangement detection in solid tumors. The Oncologist. 2026;31(3). doi:10.1093/oncolo/oyag001
BibTeX
@article{KellerEvans2026,
author = {Keller-Evans, Rachel B and Lee, Jessica K and Allen, Justin M and Zhong, Lei and Gjoerup, Ole and Ross, Jeffrey S and Gascó, Amaya and Huang, Richard S P},
title = {DNA and RNA-based next-generation sequencing for companion diagnostic rearrangement detection in solid tumors},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {3},
doi = {10.1093/oncolo/oyag001}
}
EUVIMED